Incyte Corporation is making progress toward providing vitiligo patients with therapeutic options, as it presented Phase IIb data on 11 October at the European Academy of Dermatology and Venereology Congress showing that oral selective JAK1 inhibitor povorcitinib at multiple doses can improve facial or full-body depigmentation in patients with nonsegmental vitiligo.
Incyte’s Oral JAK1 Inhibitor Shows Potential In Facial, Full Body Vitiligo
After promising Phase IIb 24-week data with povorcitinib, Incyte unveiled 52-week data indicating greater improvement with longer-term therapy and plans to initiate a Phase III trial.
More from Clinical Trials
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
More from R&D
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.